Liver Cancer

It was lovely to meet with Dr Bruno Sangro (Clínica Universidad de Navarra, Pamplona, Spain) to talk about some of the early phase data presented at EASL 2021 around immune checkpoint inhibitors in the treatment of HCC. Questions Why are patients with Child-Pugh B liver function excluded from clinical trials, and what is their prognosis? […]

We joined Ahmed Kaseb (M.D. Anderson Cancer Center) at ESMO 2019 to discuss recent findings from the randomised, open-label, perioperative phase 2 study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable hepatocellular carcinoma (NCT03222076). Questions 1. What are the major unmet needs in the treatment of resectable hepatocellular carcinoma (HCC)? (00:02) 2. […]

Combination therapy with lenvatinib and everolimus in metastatic renal cell carcinoma – why did this combination succeed where others failed? Katrina Mountfort, Touch Medical Media, Reading, UK, Metastatic renal cell carcinoma (mRCC) is associated with a poor prognosis, with a 5-year survival rate of only 8%.¹ Within the last 10 years, a number of potent […]

Liver cancer is the second leading cause of cancer-related death, and has limited treatment options and a poor prognosis.1 Mortality owing to liver cancer has increased in the past 20 years, with a reported incidence of 841,080 cases per year.2 Hepatocellular carcinoma (HCC) represents about 90% of primary liver cancer cases.1 Multiple single agent and […]

Liver cancer has contributed to an annual 30,200 deaths in the US so far in 2018.1 An overwhelming majority is due to hepatocellular carcinoma (HCC) in the setting of advanced liver disease.2 While chronic hepatitis C and alcoholic liver disease traditionally have been the most common etiologies of cirrhosis in the US, the prevalence of […]

Tyrosine kinase inhibitors (TKIs) are small anticancer molecules targeting protooncogenic tyrosine kinase signalling pathways.¹ TKIs are now therapies used routinely in the treatment of many solid tumours such as gastrointestinal stromal tumour (GIST), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), medullary thyroid cancer, breast cancer and non-small-cell lung carcinoma (Table 1). As opposed to cytotoxic […]

Tyrosine kinase inhibitors (TKIs) are small anticancer molecules targeting protooncogenic tyrosine kinase signalling pathways.¹ TKIs are now therapies used routinely in the treatment of many solid tumours such as gastrointestinal stromal tumour (GIST), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), medullary thyroid cancer, breast cancer and non-small-cell lung carcinoma (Table 1). As opposed to cytotoxic […]

As is the case with most solid tumors, gastrointestinal (GI) tumors are treated in a variety of modalities, which are used singularly or in combination, including surgery, targeted therapies, radiation, and chemotherapy. Survival rates by stage in colon and rectal cancer are given inTable 1. Cancer stem cells (CSCs) are believed to be malignant cells […]

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death, with a rising global incidence.¹ The majority of HCC occurs in the setting of liver cirrhosis, mainly due to hepatitis C virus (HCV) infection, hepatitis B viral infection, alcohol consumption, or nonalcoholic fatty liver disease. The most important development in HCC is the advent of […]